The CRISPR patent portfolio licensed via ERS (known as the CVC portfolio) is the most comprehensive collection of proprietary rights to the fundamental CRISPR/Cas9 gene editing platform. Built on the Nobel Prize winning work of Emmanuelle Charpentier and Jennifer Doudna, ERS grants non-exclusive licenses to a growing list of issued and pending patent applications globally, in all fields excluding direct use as a human therapeutic.